<DOC>
	<DOCNO>NCT02453009</DOCNO>
	<brief_summary>The aim study verify addition enzalutamide docetaxel able improve disease control first line CRPC patient .</brief_summary>
	<brief_title>Addition Enzalutamide First Line Docetaxel Castration Resistant Prostate Cancer</brief_title>
	<detailed_description>CHEIRON trial phase II randomize study compare docetaxel plus enzalutamide docetaxel alone first line castration resistant prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1 . Histologically cytologicallyconfirmed prostate adenocarcinoma . 2 . Metastatic disease . 3 . Progressive disease receive hormonal therapy surgical castration document least one following : Increase measurable disease ( RECIST 1.1 ) [ 15 ] , and/or Appearance new lesion , include bone scan consistent progressive prostate cancer , and/or Rising PSA define 2 sequential increase previous low reference value . Each value must obtain least 1 week apart . A PSA value least 2 ng/ml require study entry . Effective castration ( serum testosterone level â‰¤0.50 ng/dL ) orchiectomy and/or LHRH agonist antagonist without antiandrogens . . If patient treat LHRH agonist antagonist ( i.e. , without orchiectomy ) , therapy continue . ii . If patient either start complete androgen blockade , PSA response ( define reduction PSA sustain least 3 month ) add antiandrogen , prior antiandrogen therapy stop randomization : least 6 week bicalutamide nilutamide , least 4 week flutamide , megestrol acetate hormonal therapy . 4 . More 18 year . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 ( see Appendix 2 ) . 6 . Ability fill quality life questionnaire 7 . Patient compliance geographic proximity allow adequate followup . 8 . Presence sign date IRBapproved patient inform consent form prior enrollment study . 1 . Prior chemotherapy prostate cancer , except estramustine except adjuvant/neoadjuvant treatment complete &gt; 3 year ago . 2 . Prior treatment abiraterone acetate and/or enzalutamide 3 . Less 28 day elapse prior treatment estramustine , radiotherapy surgery time randomization . Patients may biphosphonates prior study entry . 4 . Prior isotope therapy , whole pelvic radiotherapy , radiotherapy &gt; 30 % bone marrow . 5 . History brain metastasis , uncontrolled spinal cord compression , carcinomatous meningitis new evidence brain leptomeningeal disease . 6 . History seizure condition may predispose seizure ( eg , prior cortical stroke significant brain trauma ) . History loss consciousness transient ischemic attack within 12 month randomization ; 7 . Inadequate organ bone marrow function 8 . Contraindications use corticosteroid treatment . 9 . Clinically significant cardiovascular disease 10 . Any follow within 3 month prior randomization : treatment resistant peptic ulcer disease , erosive esophagitis gastritis , infectious inflammatory bowel disease , diverticulitis , pulmonary embolism , uncontrolled thromboembolic event . 11 . Hypersensitivity reaction active pharmaceutical ingredient capsule component , include Labrasol , butylate hydroxyanisole , butylate hydroxytoluene ; 12 . Prior malignancy . Adequately treat basal cell squamous cell skin superficial ( pTis , pTa , pT1 ) bladder cancer allow , well cancer chemotherapy complete &gt; 5 year ago patient diseasefree &gt; 5 year . 13 . Participation another clinical trial concurrent treatment investigational drug within 30 day prior randomization . 14 . Any condition judgment investigator would place subject undue risk interfere study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>